ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 170 filers reported holding ASCENDIS PHARMA A/S in Q3 2021. The put-call ratio across all filers is 1.45 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $23,606,000 | +6.1% | 179,446 | +4.0% | 0.03% | 0.0% |
| Q1 2021 | $22,242,000 | -15.4% | 172,584 | +9.5% | 0.03% | -17.1% |
| Q4 2020 | $26,291,000 | +36.3% | 157,636 | +26.1% | 0.04% | +25.0% |
| Q3 2020 | $19,292,000 | +3.2% | 125,010 | -1.1% | 0.03% | -6.7% |
| Q2 2020 | $18,693,000 | +42.4% | 126,390 | +8.4% | 0.03% | +11.1% |
| Q1 2020 | $13,129,000 | -19.9% | 116,595 | -1.1% | 0.03% | -3.6% |
| Q4 2019 | $16,399,000 | +34.2% | 117,881 | -7.1% | 0.03% | +16.7% |
| Q3 2019 | $12,220,000 | +4.9% | 126,867 | +25.4% | 0.02% | +9.1% |
| Q2 2019 | $11,653,000 | -7.8% | 101,203 | -5.7% | 0.02% | -12.0% |
| Q1 2019 | $12,635,000 | +87.2% | 107,344 | -0.3% | 0.02% | +56.2% |
| Q4 2018 | $6,748,000 | +8.1% | 107,703 | +22.3% | 0.02% | +33.3% |
| Q3 2018 | $6,240,000 | – | 88,055 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 7,387,900 | $1,177,557,000 | 16.32% |
| Q Global Advisors, LLC | 66,714 | $10,634,000 | 8.85% |
| Ghost Tree Capital, LLC | 120,000 | $19,127,000 | 5.59% |
| Vivo Capital, LLC | 760,606 | $121,233,000 | 5.44% |
| Spyglass Capital Management LLC | 1,378,887 | $219,781,000 | 5.04% |
| Avoro Capital Advisors LLC | 1,980,000 | $315,592,000 | 4.96% |
| Eversept Partners, LP | 445,203 | $70,960,906 | 4.93% |
| Sofinnova Investments, Inc. | 499,824 | $79,667,000 | 4.72% |
| Eventide Asset Management | 1,748,648 | $278,717,000 | 3.68% |
| Baker Brothers Advisors | 4,541,604 | $723,886,000 | 3.18% |